



A graphical review on the escalation of fused deposition modeling (FDM) 3D printing in the pharmaceutical field

Journal:	<i>Journal of Pharmaceutical Sciences</i>
Manuscript ID	20-434.R2
Article Type:	Review
Date Submitted by the Author:	n/a
Complete List of Authors:	Melocchi, Alice; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Uboldi, Marco; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Cerea, Matteo; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Foppoli, Anastasia; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Maroni, Alessandra; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Moutaharrik, Saliha; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Palugan, Luca; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Zema, Lucia; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM) Gazzaniga, Andrea; Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM)
Keywords:	Printing (3D), Solid dosage form(s), Controlled release, Polymeric drug delivery system(s), Drug delivery system(s)

1
2
3 **A graphical review on the escalation of fused deposition modeling (FDM) 3D**
4 **printing in the pharmaceutical field**
5
6
7
8
9
10
11

12 Alice Melocchi, Marco Uboldi, Matteo Cerea, Anastasia Foppoli, Alessandra Maroni, Saliha
13 Moutaharrik, Luca Palugan, Lucia Zema*, Andrea Gazzaniga
14
15
16
17
18
19

20 Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", Dipartimento di
21 Scienze Farmaceutiche, Università degli Studi di Milano, via G. Colombo 71, 20133 Milano, Italy.
22
23
24
25
26
27

28 * corresponding author: lucia.zema@unimi.it, Tel.: 0039 02 50324654
29
30
31

32 **Keywords:** 3D Printing; Solid dosage form; Controlled release; Drug delivery system; Polymeric
33 drug delivery system; 4D printing, Fused deposition modeling.
34
35
36
37
38
39
40
41

42 **Abstract**
43

44 Fused deposition modeling (FDM) 3D printing is currently one of the hot topics in pharmaceutics and
45 has shown a 2000% increase in the number of research articles published in the last 5 years. In the
46 prospect of a new era of FDM focused on the industrial development of this technique applied to the
47 fabrication of personalized medicines, a conceptual map to move through the evolution of the design
48 of the printed dosage forms/drug delivery systems was conceived and mainly discussed by means of
49 graphical tools.
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

Starting from 2014, fused deposition modeling (FDM) 3D printing has become a hot topic in the pharmaceutical field. This technique makes use of a filament, generally obtained starting from a thermoplastic polymer by hot melt extrusion (HME), as starting material. The filament is driven, through a geared system, into the heated block of the printer for softening or melting. In this way, subsequent layers of material could be deposited, through a nozzle, onto the 3D printer build plate. The overlaid layers fuse and, following cooling, bond to each other, thus allowing one to obtain the final 3D object. As FDM involves the deposition of subsequent layers obtained by the extrusion of molten/softened formulations, it is characterized by strong similarities with other hot-processing techniques that have already found application in the pharmaceutical field, such as HME.

FDM moved from just appearing in the experimental section of published papers to become the true key player of research. With respect to the former application, it was tested as a rapid and economical method to produce plastic prototypes of different shapes for casting molds having specular cavities¹⁻⁵. These were then used for the fabrication of drug-containing systems following assembly and welding of different parts previously manufactured *via* other techniques and placed within the mold cavity. On the other hand, the real first attempts to demonstrate feasibility of FDM for direct fabrication of printed dosage forms / drug delivery systems (DDSs) were carried out in parallel by several research groups⁶⁻¹¹. Following these essential inputs, the overall research activity of subsequent years exhibited the full potential of this technology and its main advantages. However, many challenges have yet to be addressed for enabling the actual printing of personalized medicines safe for human administration, thus launching a new FDM era.

Aware that any advancement requires a deep knowledge of the relevant background, we used the graphical tool and a language made of images to highlight the evolution of FDM in the pharmaceutical field and the variety of the applications proposed so far in the scientific literature, in terms of design and route of administration. An attempt was made to consider all journals, not only those belonging to the pharmaceutical area, and to include all the research groups currently working on FDM. A

1
2
3 schematic overview of the critical parameters impacting the quality of the FDM process, and therefore
4 of the final product (*i.e.* starting materials, hardware and software characteristics, and manufacturing
5 environment), are collected in Figure 1. Research and review articles specifically focused on FDM,
6
7
8 published from 2014 to the present date, were employed for the construction of a graphical discussion,
9
10
11
12 *i.e.* to visually display and quantify:

- 13
14
15 *i)* the key-factors associated with the developments of the technique in the field of pharmaceutical
16
17 research (Figure 2),
- 18
19
20 *ii)* the times and sources chosen for dissemination (Figure 3),
- 21
22
23
24
25 *iii)* the different applications taken into consideration over time (*e.g.* administration routes
26
27 proposed) (Figure 4),
- 28
29
30
31
32 *iv)* the complexity of the systems proposed, especially in terms of design (Figure 5).

33
34
35 In this way, we aimed to provide the readers with a concept map of the DDSs manufactured by FDM
36
37 since the beginning of its application in the pharmaceutical field.

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 Images are supposed to reflect meanings more directly than words and to be easier to recall. As they
can also generate a verbal label (while words are not likely to generate image labels), a few highlights
are summarized for each figure in the form of bullet points¹²⁻¹⁷. Moreover, for each category
identified in the concept map, a choice was made to develop schematic representations of the main
DDSs proposed, highlighting similarities and differences relevant to their geometry / design (Figure
6-16). By way of example, in a few cases, details were also reported (indicated with the magnifying
glass symbol) providing insight into the internal structure, content or working mechanism of the
systems. Formulation issues, such as the choice of technological and performance aids, and the
addition of active ingredients, either during or after the fabrication process (*e.g.* by soaking), were
necessarily omitted as they cannot be easily described by images. Indeed, this topic has already been
covered in depth elsewhere¹⁸⁻³⁵. The selected approach would make the readers take advantage of
any possible picture superiority effect. In this respect, showing the design of the systems proposed
would fulfill different objectives, such as making the audience curious about specific articles, easily

recognizing possible similarities in the research work, enabling identification of groups that are facing the same challenges, and laying down the bases for new applications of this technique.

2. Graphical discussion

Figure 1




Figure 2





Figure 3



Review

Figure 4



Figure 5





Figure 6



For Peer Review

Figure 7



Figure 8



Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14





Figure 15



Figure 16



3. Conclusions

Since 2014, dosage forms / DDSs fabricated by FDM have rapidly grown in number and complexity in terms of shape, composition and use, covering different routes of administration and performance targets. An insight into the literature relevant to pharmaceutical applications of FDM, other than those described in patents or concerning the fabrication of casting molds^{184,185}, was provided through the use of graphics and images. These were effective in visualizing the common aspects, but also the peculiarities / details that gradually promoted small and greater advances in the field. However, both quality assurance and quality control topics, as well as formulation choices still represent limitations, especially with regard to the expected performance and resolution goals. For the same reason, no drug products manufactured by FDM have been approved yet. Relying on the experience gained thus far, this manuscript could help to develop ideas to consolidate the results obtained to date and open up inspiring perspectives in the use of FDM in the pharmaceutical industry, possibly inaugurating a new era for such a technique.

1
2
3 The data that support the findings of this study are available from the corresponding author upon
4
5 request.
6

7
8 The authors did not receive any funding for this work.
9

10 The authors declare that there is no conflict of interest regarding the publication of this article.
11
12
13

14 **References**

- 15
16
17 1. Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YL,
18 Mazdiyasni H, Kogan, L, Barman R, Cleveland C, Booth L, BenseL T, Minahan D, Hurowitz,
19 HM, Tai T, Daily J, Nikolic B, Wood L, Eckhoff PA, Langer R, Traverso G. Oral, ultra-long-
20 lasting drug delivery: application toward malaria elimination goals. *Sci Transl Med*
21 2016,8:365ra157.
22
23
- 24
25
26
27
28 2. Kirtane AR, Abouzid O, Minahan D, BenseL T, Hill AL, Selinger C, Bershteyn A, Craig M, Mo
29 SS, Mazdiyasni H, Cleveland C, Rogner J, LeeYL, Booth L, Javid F, Wu SJ, Grant T, Bellinger
30 AM, Nikolic B, Hayward A, Wood L, Eckhoff PA, Nowak MA, Langer R, Traverso G.
31 Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. *Nat*
32 *Commun* 2018,9:2.
33
34
- 35
36
37
38
39 3. Kirtane AR, Abouzid O, Minahan D, BenseL T, Hill AL, Selinger C, Bershteyn A, Craig M, Mo
40 SS, Mazdiyasni H, Cleveland C, Rogner J, Lee YL, Booth L, Javid F, Wu SJ, Grant T, Kirtane
41 AR, Hua T, Hayward A, Bajpayee A, Wahane A, Lopes A, BenseL T, Ma L, Stanczyk FZ,
42 Brooks S, Gwynne D, Wainer J, Collins J, Tamang SM, Langer R, Traverso G. A once-a-month
43 oral contraceptive. *Sci Transl Med* 2019,11:eaay2602.
44
45
- 46
47
48
49
50
51 4. Kong YL, Zou X, McCandler CA, Kirtane AR, Ning S, Zhou J, Abid A, Jafari M, Rogner J,
52 Minahan D, Collins JE, McDonnell S, Cleveland C, BenseL T, TamangS, Arrick G, Gimbel A,
53 Hua T, Ghosh U, Soares V, Wang N, Wahane A, Hayward A, Zhang S, Smith BR, Langer R,
54 Traverso G. 3D-printed gastric resident electronics. *Adv Mater Technol* 2018,1800490.
55
56
57
58
59
60

- 1
2
3 5. Zhang S, Bellinger AM, Gletting DL., Barman R, Lee Y-AL, Zhu J, Cleveland C, Montgomery
4 VA, Gu L, Nash LD, Maitland DJ, Langer R, Traverso G. A pH-responsive supramolecular
5 polymer gel as an enteric elastomer for use in gastric devices. *Nat. Mater.* 2015,14:1065-1070.
6
7
- 8
9
10 6. Goyanes A, Buanz ABM, Basit AW, Gaisford S. Fused-filament 3D printing (3DP) for
11 fabrication of tablets. *Int J Pharm* 2014,476:88-92.
12
- 13
14 7. Melocchi A, Parietti F, Loreti G, Maroni A, Zema L, Gazzaniga A. 3D-printing: application
15 potential for the manufacturing of drug delivery systems in the form of capsular devices, Annual
16 Workshop of the CRS Italy Chapter "Nanomedicine: pharmacokinetic challenges, targeting and
17 **clinical outcomes**", Florence, November 6-8, 2014,
18 [http://users.unimi.it/gazzalab/wordpress/wp-content/uploads/2020/06/Extended-CRS-Italy-
19 3D-printing-final.pdf](http://users.unimi.it/gazzalab/wordpress/wp-content/uploads/2020/06/Extended-CRS-Italy-3D-printing-final.pdf).
20
21
22
23
24
25
26
27
- 28 8. Melocchi A, Parietti F, Loreti G, Maroni A, Gazzaniga A, Zema L. 3D printing by fused
29 deposition modeling (FDM) of a swellable/erodible capsular device for oral pulsatile release of
30 drugs. *J Drug Deliv Sci Tech* 2015,30 Part B:360-367.
31
32
- 33 9. Pietrzak K, Isreb A, Alhnan MA. A flexible-dose dispenser for immediate and extended release
34 3D printed tablets. *Eur J Pharm Biopharm* 2015,96:380-387.
35
36
37
38
- 39 10. Sandler N, Salmela I, Fallarero A, Rosling A, Khajeheian M, Kolakovic R, Genina N, Nyman
40 J, Vuorela P. Towards fabrication of 3D printed medical devices to prevent biofilm formation.
41 *Int J Pharm* 2014,459:62-64.
42
43
44
45
- 46 11. Weisman JA, Nicholson JC, Tappa K, Jammalamadaka U, Wilson CG, Mills D. Antibiotic and
47 chemotherapeutic enhanced three-dimensional printer filaments and constructs for biomedical
48 applications. *Int J Nanomed* 2015,10:357-370.
49
50
51
- 52 12. Bucchi M, Saracino B. "Visual Science Literacy": images and public understanding of science
53 in the digital age, *Sci Commun* 2016, 38: 812-819.
54
55
56
- 57 13. Eitel A, Scheiter K, Schüler A, Nyström M, Holmqvist K. How a picture facilitates the process
58 of learning from text: evidence for scaffolding. *Learn Instr* 2013,13:48-63.
59
60

14. Mayer RE, Sims VK. For whom is a picture worth a thousand words? Extensions of a dual-coding theory of multimedia learning. *J Educ Psychol* 1994,86:389-401.
15. Rodríguez Estrada FC, Davis LD. Improving visual communication of science through the incorporation of graphic design theories and practices into science communication. *Sci Commun* 2014,37:140-148.
16. Trumbo J. Visual literacy and science communication. *Sci. Commun.* 1999,20:409-425.
17. Whitehouse AJO, Maybery MT, Durkin K. The development of the picture-superiority effect. *Br J Dev Psychol* 2010,24:767-773.
18. Alhnan MA, Okwuosa TC, Sadia M, Wan KW., Ahmed W, Arafat B. Emergence of 3D printed dosage forms: opportunities and challenges. *Pharm Res* 2016,33:1817-1832.
19. Alomari M, Mohamed FH, Basit AW, Gaisford S. Personalised dosing: printing a dose of one's own medicine. *Int J Pharm* 2015,494:568-577.
20. Awad A, Trenfield S J, Goyanes A, Gaisford S, Basit AW. Reshaping drug development using 3D printing. *Drug Discov Today* 2018,23: 547-1555.
21. Chandekar A, Mishra DK, Sharma S, Saraogi GK, Gupta U, Gupta G. 3D printing technology: a new milestone in the development of pharmaceuticals. *Current Pharm Design* 2019, 25:937-945.
22. Lamichhane S, Bashyal S, Keum T, Noh G, Jo S, Rakesh E, Choi B, Sohn J., Hwan D, Sangkil L. Complex formulations, simple techniques: can 3D printing technology be the Midas touch in pharmaceutical industry?. *Asian J Pharm Sci* 2019,14:465-479.
23. Liang K, Brambilla D, Leroux J-C. Is 3D printing of pharmaceuticals a disruptor or enabler?. *Adv Mater* 2019,31:e1805680.
24. Norman J, Madurawe RD, Moore CMV, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. *Adv Drug Deliv Rev* 2017,108:39-50.

- 1
- 2
- 3 25. Palo M, Holländer J, Suominen J, Yliruusi J, Sandler N. 3D printed drug delivery devices:
- 4 perspectives and technical challenges. *Expert Rev Med Devices* 2017,14:685-696.
- 5
- 6
- 7 26. Prasad LK, Smyth H. 3D Printing technologies for drug delivery: a review. *Drug Dev Ind Pharm*
- 8 2016,42:1019-1031.
- 9
- 10
- 11
- 12 27. Preis M, Öblom H. 3D-printed drugs for children-are we ready yet?. *AAPS PharmSciTech*
- 13 2017,18:303-308.
- 14
- 15
- 16 28. Sandler N, Preis M. Printed drug-delivery systems for improved patient treatment. *Trends*
- 17 *Pharmacol Sci* 2017, 37:1070-1080.
- 18
- 19
- 20 29. Souto EB, Campos JC, Filho SC., Teixeira MC., Martins-Gomes C, Zielinska A, Carbone C,
- 21 Silva AM. 3D printing in the design of pharmaceutical dosage forms. *Pharm Dev Technol*
- 22 2019,24:1044-1053.
- 23
- 24
- 25
- 26
- 27 30. Trenfield SJ, Awad A, Goyanes A, Gaisford S, Basit AW. 3D printing pharmaceuticals: drug
- 28 development to frontline care. *Trends Pharmacol Sci* 2018,39:440-451.
- 29
- 30
- 31 31. Trenfield SJ, Madla CM, Basit AW, Gaisford S. The shape of things to come: emerging
- 32 applications of 3D printing in healthcare. In: *3D Printing of Pharmaceuticals*, 1st ed., Basit A
- 33 W, Gaisford S. Eds., London: Springer, 2018:1-19.
- 34
- 35
- 36 32. Trenfield SJ, Awad A, Madla CM, Hatton GB., Firth J, Goyanes A, Gaisford S, Basit AW.
- 37 Shaping the future, recent advances of 3D printing in drug delivery and healthcare. *Expert Opin*
- 38 *Drug Deliv* 2019,16:1081-1094.
- 39
- 40
- 41 33. Warsi MH, Yusuf M, Al Robaian M, Khan M, Muheem A, Khan S. 3D printing methods for
- 42 pharmaceutical manufacturing: opportunity and challenges. *Cur Pharm Des* 2018,24:4949-
- 43 4956.
- 44
- 45
- 46 34. Zema L, Melocchi A, Maroni A, Gazzaniga A. Three-dimensional printing of medicinal
- 47 products and the challenge of personalized therapy. *J Pharm Sci* 2017,106:1697-1705.
- 48
- 49
- 50
- 51 35. Zhang J, Vo AQ, Feng X, Bandari S, Repka MA. Additive manufacturing: a novel tool for
- 52 complex and personalized drug delivery systems. *AAPS PharmSciTech* 2018,19: 3388-3402.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 36. Ehtezazi T, Algellay M, Islam Y, Roberts M, Dempster NM, Sarker SD. The Application of 3D
4 printing in the formulation of multilayered fast dissolving oral films. J Pharm
5 Sci 2018,107:1076-1085.
6
7
8
9
10 37. Eleftheriadis GK, Ritzoulis C, Bouropoulos N, Tzetzis D, Andreadis DA, Boetker J, Rantanen
11 J, Fatouros G. Unidirectional drug release from 3D printed mucoadhesive buccal films using
12 FDM technology: *in vitro* and *ex vivo* evaluation. Eur J Pharm Biopharm 2019,144:180-192.
13
14
15
16 38. Jamróz W, Kurek M, Łyszczarz E, Szafranec J, Knapik-Kowalczyk J, Syrek K, Paluch M,
17 Jachowicz R. 3D printed orodispersible films with aripiprazole. Int J Pharm 2017,533:413-420.
18
19
20 39. Musazzi UM, Selmin F, Ortenzi MA, Mohammed GK., Franzé S, Minghetti P, Cilurzo F.
21 Personalized orodispersible films by hot melt ram extrusion 3D printing. Int J Pharm
22 2018,551:52-59.
23
24
25
26 40. Arafat B, Qinna N, Cieszyńska M, Forbes R.T, Alhnan MA. Tailored on demand anti-coagulant
27 dosing: an *in vitro* and *in vivo* evaluation of 3D printed purpose-designed oral dosage forms.
28 Eur J Pharm Biopharm 2018,128:282-289.
29
30
31
32 41. Arafat B, Wojsz M, Isreb A, Forbes RT, Isreb M., Ahmed W, Arafat T., Alhnan MA. Tablet
33 fragmentation without a disintegrant: a novel design approach for accelerating disintegration
34 and drug release from 3D printed cellulosic tablets. Eur J Pharm Sci 2018,118:191-199.
35
36
37
38 42. Cerda JR, Arifi T, Ayyoubi S, Knief P, Ballesteros MP, Keeble W, Barbu E, Healy AM Lalatsa,
39 A, Serrano DR. Personalised 3D printed medicines: optimising material properties for
40 successful passive diffusion loading of filaments for fused deposition modelling of solid dosage
41 forms. Pharmaceutics 2020,12:345.
42
43
44
45 43. Chai X, Chai H, Wang X, Yang J, Li J, Zhao Y, Cai W, Tao T, Xiang X. Fused Deposition
46 Modeling (FDM) 3D printed tablets for intragastric floating delivery of domperidone. Scientific
47 Rep 2017,7:2829.
48
49
50
51 44. Chen D, Xu X-Y, Li R, Zang G-A, Zhang Y, Wang M-R, Xiong M-F, Xu J-R, Wang T, Fu H,
52 Hu Q, Wu B, Yan G-R, Fan T-Y. Preparation and *in vitro* Evaluation of FDM 3D-printed
53
54
55
56
57
58
59
60

- 1
2
3 ellipsoid-shaped gastric floating tablets with low infill percentages. *AAPS PharmSciTech*
4
5 2020,21:6.
6
7
8 45. Chew LS, de Mohac LM, Raimi-Abraham BT. 3D-printed solid dispersion drug products.
9
10 *Pharmaceutics* 2019,11:672.
11
12 46. Fanous M, Gold S, Muller S, Hirsch S, Ogorka J, Imanidis G. Simplification of fused deposition
13 modeling 3D-printing paradigm: feasibility of 1-step direct powder printing for immediate
14 release dosage form production. *Int J Pharm* 2020, 578:119124.
15
16
17 47. Fastø MM, Genina N, Kaae S, Kälvemark Sporrøng S. Perceptions, preferences and
18 acceptability of patient designed 3D printed medicine by polypharmacy patients: a pilot study.
19
20 *Int J Clin Pharm* 2019,41:1290-1298.
21
22
23 48. Giri BR, Song ES., Kwon J, Lee J-H., Park J-B, Kim DW. Fabrication of intragastric floating,
24 controlled release 3D printed theophylline tablets using hot-melt extrusion and fused deposition
25 modeling. *Pharmaceutics* 2020,12:77.
26
27
28 49. Goyanes A, Buanz ABM., Hattn GB, Gaisford S., Basit AW. 3D printing of modified-release
29 aminosalicylate (4-ASA and 5-ASA) tablets. *Eur J Pharm Biopharm* 2015,89:157-162.
30
31
32 50. Goyanes A, Chang H, Sedough D, Hatton GB, Wang J, Buanz A, Gaisford S, Basit AW.
33 Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing. *Int J*
34 *Pharm* 2015, 96:414-420.
35
36
37 51. Goyanes A, Robles Martinez P, Buanz A., Basit AW., Gaisford S. Effect of geometry on drug
38 release from 3D printed tablets. *Int J Pharm* 2015, 494:657-663.
39
40
41 52. Goyanes A, Kobayashi M, Martínez-Pacheco R, Gaisford S, Basit AW. Fused-filament 3D
42 printing of drug products: microstructure analysis and drug release characteristics of PVA-
43 based caplets. *Int J Pharm* 2016,514:290-295.
44
45
46 53. Goyanes A, Fina F, Martorana A, Sedough D, Gaisford S, Basit AW. Development of modified
47 release 3D printed tablets (printlets) with pharmaceutical excipients using additive
48 manufacturing. *Int J Pharm* 2017,527:21-30.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 54. Goyanes A, Scarpa M, Kamlow M, Gaisford S, Basit AW, Orlu M. Patient acceptability of 3D
4 printed medicines. *Int J Pharm* 2017,530:71-78.
5
6
7 55. Goyanes A, Allahham N, Trenfield SJ, Stoyanov E, Gaisford S, Basit AW. Direct powder
8 extrusion 3D printing: fabrication of drug products using a novel single-step process, *Int J*
9 *Pharm* 2019, 567:118471.
10
11
12
13
14 56. Gültekin HE, Tort S Acartürk F. An effective technology for the development of immediate
15 release solid dosage forms containing low-dose drug: fused deposition modeling 3D printing.
16 *Pharm Res* 2019,36:128.
17
18
19
20
21 57. Ibrahim M, Barnes M, McMillin R, Cook DW., Smith S, Halquist M, Wijesinghe D, Roper TD.
22 3D printing of metformin HCl PVA tablets by fused deposition modeling: drug loading, tablet
23 design, and dissolution studies. *AAPS PharmSciTech* 2019,20:195.
24
25
26
27
28 58. Ilyés K, Balogh A, Casian T, Igricz T, Borbás E, Démuth B, Vass P, Menyhárt L, Kovács NK,
29 Marosi G, Tomuță I, NagyZK. 3D floating tablets: appropriate 3D design from the perspective
30 of different *in vitro* dissolution testing methodologies. *Int J Pharm* 2019,567:118433.
31
32
33
34
35 59. Isreb A Baj K, Wojsz M, Isreb M, Peak M, Alhnan MA. 3D printed oral theophylline doses
36 with innovative ‘radiator-like’ design: Impact of polyethylene oxide (PEO) molecular weight.
37 *Int J Pharm* 2019,564:98-105.
38
39
40
41
42 60. Kempin W, Domsta V, Grathoff G, Brecht I, Semmling B, Tillmann S, Weitschies W, Seidlitz
43 A. Immediate release 3D-printed tablets produced *via* fused deposition modeling of a thermo-
44 sensitive drug. *Pharm Res* 2018,35:124.
45
46
47
48
49 61. Khorasani M, Edinger M, Rajjada D., Bøtker J, AhoJ., Rantanen J. Near-infrared chemical
50 imaging (NIR-CI) of 3D printed pharmaceuticals. *Int. J. Pharm.* 2016,515:324-330.
51
52
53
54 62. Kimura S-I, Ishikawa T, Iwao, Y., Itai, S., Kondo, H. Fabrication of zero-order sustained-
55 release floating tablets *via* fused depositing modeling 3D printer. *Chem Pharm Bull* 2019,67:
56 992-999.
57
58
59
60

- 1
2
3 63. Kollamaram G, Croker DM, Walker GM, Goyanes A, Basit AW, Gaisford S. Low temperature
4 fused deposition modeling (FDM) 3D printing of thermolabile drugs, *Int J Pharm* 2018, 545:
5 144-152.
6
7
8
9
10 64. Korte C, Quodbach J. 3D-printed network structures as controlled-release drug delivery
11 systems: dose adjustment, API release analysis and prediction. *AAPS PharmSciTech*
12 2018,19:3333-3342.
13
14
15
16
17 65. Lamichhane S, Park J-B, Sohn DH, Lee S. Customized novel design of 3D printed pregabalin
18 tablets for intra-gastric floating and controlled release using fused deposition modeling.
19 *Pharmaceutics* 2019,11:564.
20
21
22
23
24 66. Li Q, Guan X, Cui M, Zhu Z, Chen K, Wen H, Jia D, Hou J, Xu W, Yang X, Pan W. Preparation
25 and investigation of novel gastro-floating tablets with 3D extrusion-based printing. *Int J Pharm*
26 2018,535:325-332.
27
28
29
30
31 67. Matijašić G, Gretić M, Kezerić K, Petanjek J, Vukelić E. Preparation of filaments and the 3D
32 printing of dronedarone HCl tablets for treating cardiac arrhythmias. *AAPS PharmSciTech*
33 2019,20:310.
34
35
36
37
38 68. Melocchi A, Uboldi M, Inverardi N, Briatico-Vangosa F, Baldi F, Pandini S, Scalet G,
39 Auricchio F, Cerea M, Foppoli A, Maroni A, Zema L, Gazzaniga A. Expandable drug delivery
40 system for gastric retention based on shape memory polymers: development via 4D printing
41 and extrusion. *Int J Phar* 2019, 571:118700.
42
43
44
45
46
47 69. Novák M, Boleslavská T, Grof Z, Waněk A, Zadražil A, Beránek J, Kovačik P, Štěpánek F.
48 Virtual **prototyping** and parametric design of 3D-printed tablets based on the solution of inverse
49 problem. *AAPS PharmSciTech* 2018,19:3414-3424.
50
51
52
53
54 70. Nukala PK, Palekar S, Patki M, Patel K. Abuse deterrent immediate release egg-shaped tablet
55 (Egglets) using 3D printing technology: quality by design to optimize drug release and
56 extraction. *AAPS PharmSciTech* 2019,20:80.
57
58
59
60

- 1
2
3 71. Nukala PK, Palekar S, Solanki N, Fu Y, Patki M, Sohatee AA, Trombetta L, Patel K.
4 Investigating the application of FDM 3D printing pattern in preparation of patient-tailored
5 dosage forms. *J 3D PrintMed* 2019,3:23-37.
6
7
8
9
10 72. Öblom H, Zhang J, Pimparade M, Speer I, Preis M, Repka, M, Sandler, N. 3D-printed isoniazid
11 tablets for the treatment and prevention of tuberculosis - personalized dosing and drug release.
12 *AAPS PharmSciTech* 2019,20:52.
13
14
15
16 73. Okwuosa TC, Stefaniak D, Arafat B, Isreb A, Wan K-W, Alhnan M. A lower temperature FDM
17 3D printing for the manufacture of patient-specific immediate release tablets. *Pharm Res* 2016,
18 33:2704-2712.
19
20
21
22
23 74. Ong JJ, Awad A, Martorana A, Gaisford S, Stoyanov E, Basit AW, Goyanes A. 3D printed
24 opioid medicines with alcohol-resistant and abuse-deterrent properties. *Int J Pharm*
25 2020,579:119169.
26
27
28
29
30 75. Palekar S, Nukala PK, Mishra SM, Kipping T, Patel K. Application of 3D printing technology
31 and quality by design approach for development of age-appropriate pediatric formulation of
32 baclofen. *Int J Pharm* 2019,556:106-116.
33
34
35
36
37 76. Sadia M, Sośnicka A, Arafat B, Isreb A, Ahmed W, Kellarakis A, Alhnan MA, Adaptation of
38 pharmaceutical excipients to FDM 3D printing for the fabrication of patient-tailored immediate
39 release tablets. *Int J Pharm* 2016,513:659-668.
40
41
42
43
44 77. Sadia M, Arafat B, Ahmed W, Forbes RT, Alhnan MA. Channelled tablets: an innovative
45 approach to accelerating drug release from 3D printed tablets. *J Control Release* 2018,269:355-
46 363.
47
48
49
50 78. Saviano M, Aquino RP, Del Gaudio P, Sansone F, Russo P. Poly(vinyl alcohol) 3D printed
51 tablets: the effect of polymer particle size on drug loading and process efficiency. *Int J Pharm*
52 2019,561:1-8.
53
54
55
56 79. Scoutaris N, Ross SA, Douroumis D. 3D printed “Starmix” drug loaded dosage forms for
57 paediatric applications. *Pharm Res* 2018,35:34.
58
59
60

- 1
2
3 80. Solanki NG, Tahsin M, Shah AV, Serajuddin ATM. Formulation of 3D printed tablet for rapid
4 drug release by fused deposition modeling: screening polymers for drug release, drug-polymer
5 miscibility and printability. *J Pharm Sci* 2018, 107:390-401.
6
7
8
9
10 81. Tagami T, Kuwata E, Sakai N, Ozeki T. Drug incorporation into polymer filament using simple
11 soaking method for tablet preparation using fused deposition modeling. *Biol Pharm Bull*
12 2019,42:1753-1760.
13
14
15
16 82. Verstraete G, Samaro A, Grymonpré W, Vanhoorne V, Van Snick B, Boone MN, Hellemans
17 T, Van Hoorebeke L, Remon JP, Vervaeck C. 3D printing of high drug loaded dosage forms
18 using thermoplastic polyurethanes. *Int J Pharm* 2018, 536, 318-325.
19
20
21
22
23 83. Wei C, Solanki NG, Vasoya JM., Shah AV, Serajuddin ATM. Development of 3D printed
24 tablets by fused deposition modeling using polyvinyl alcohol as polymeric matrix for rapid drug
25 release, *J Pharm Sci* 2020,109:1558-1572.
26
27
28
29
30 84. Yang Y, Wang H, Li H, Ou Z, Yang G. 3D printed tablets with internal scaffold structure using
31 ethyl cellulose to achieve sustained ibuprofen release. *Eur J Pharm Sci* 2018,115:11-18.
32
33
34
35 85. Zhang J, Feng X, Patil H, Tiwari RV, Repka MA. Coupling 3D printing with hot-melt extrusion
36 to produce controlled-release tablets. *Int J Pharm* 2017,519:186-197.
37
38
39
40 86. Zhang J, Yang W, Vo AQ, Feng X, Ye X, Kim DW, Repka MA. Hydroxypropyl
41 methylcellulose-based controlled release dosage by melt extrusion and 3D printing: structure
42 and drug release correlation, *Carbohydr Polym* 2017,177:49-57.
43
44
45
46 87. Gioumouxouzis CI, Katsamenis OL., Bouropoulos N, Fatouros DG. 3D printed oral solid
47 dosage forms containing hydrochlorothiazide for controlled drug delivery, *J Drug Deliv Sci*
48 *Technol* 2017, 40:164-171.
49
50
51
52
53 88. Gioumouxouzis CI, Baklavaridis A, Katsamenis OL, Markopoulou CK, Bouropoulos N,
54 Tzetzis D, Fatouros DG. A 3D printed bilayer oral solid dosage form combining metformin for
55 prolonged and glimepiride for immediate drug delivery. *Eur J Pharm Sci* 2018, 120:40-52.
56
57
58
59
60

- 1
2
3 89. Gioumouxouzis CI, Tzimtzimis E, Katsamenis OL, DourouA., Markopoulou C, Bouropoulos
4 N, Tzetzis D, Fatouros DG. Fabrication of an osmotic 3D printed solid dosage form for
5 controlled release of active pharmaceutical ingredients. *Eur J Pharm Sci* 2020,143:105176.
6
7
8
9
10 90. Goyanes A, Wang J, Buanz A, Martínez-Pacheco R, Telford R, Gaisford S Basit AW. 3D
11 printing of medicines: engineering novel oral devices with unique design and drug release
12 characteristics. *Mol Pharm* 2015,12:4077-4084.
13
14
15
16
17 91. Jamróz W, Kurek M, Czech A, Szafraniec J, Gawlak K, Jachowicz R, 3D printing of tablets
18 containing amorphous aripiprazole by filaments co-extrusion, *Eur J Pharm Biopharm*
19 2018,131:44-47.
20
21
22
23
24 92. Jamróz W, Kurek M, Szafraniec-Szczęśny J, Czech A, Gawlak K, Knapik-Kowalczyk J,
25 Leszczyński B, Wróbel A., Paluch M, Jachowicz R. Speed it up, slow it down...An issue of
26 bicalutamide release from 3D printed tablets. *Eur J Pharm* 2020,143:105169.
27
28
29
30
31 93. Kadry H, Al-Hilal TA, Keshavarz A, Alam F, Xu C, Joy A, Ahsan F, Multi-purposable
32 filaments of HPMC for 3D printing of medications with tailored drug release and timed-
33 absorption. *Int J Pharm*, 2018,544:285-296.
34
35
36
37
38 94. Kempin W, Domsta V, Brecht I, Semmling B, TillmannS., Weitschies W, Seidlitz A.
39 Development of a dual extrusion printing technique for an acid- and thermo-labile drug. *Eur J*
40 *Pharm Sci* 2018,123:191-198.
41
42
43
44
45 95. Li Q, Wen H, Jia D, Guan X, Pan H, Yang Y, YuS., Zhu Z, Xiang R, Pan W. Preparation and
46 investigation of controlled-release glipizide novel oral device with three-dimensional printing.
47 *Int J Pharm* 2017,525:5-11.
48
49
50
51
52 96. Okwuosa TC Pereira BC, Arafat B, Cieszyńska M, Isreb A, Alhnan MA. Fabricating a shell-
53 core delayed release tablet using dual FDM 3D printing for patient-centred therapy. *Pharm Res*
54 2017,34:427-437.
55
56
57
58
59
60

- 1
2
3 97. Pereira BC, Isreb A ForbesRT, Dores F, Habashy R, Petit J-B, Alhnan MA Oga EF. Temporary
4 Plasticiser': a novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill'
5 architectures. *Eur J Pharm Biopharm* 2019,135:94-103.
6
7
8
9
10 98. Sadia M, Isreb A, Abbadi I, Isreb M, Aziz D, Selo A, Timmins P, Alhnan MA. From 'fixed
11 dose combinations' to 'a dynamic dose combiner': 3D printed bi-layer antihypertensive tablets.
12 *Eur J Pharm Sci* 2018,123:484-494.
13
14
15
16 99. Tagami T, Nagata N, Hayashi N, Ogawa E, FukushigeK., Sakai N Ozeki T. Defined drug
17 release from 3D-printed composite tablets consisting of drug-loaded polyvinylalcohol and a
18 water-soluble or water-insoluble polymer filler. *Int J Pharm* 2018,543:361-367.
19
20
21
22
23 100. Beck RCR, Chaves PS, Goyanes A, Vukosavljevic B, Buanz A, Windbergs M, Basit AW,
24 Gaisford S. 3D printed tablets loaded with polymeric nanocapsules: an innovative approach to
25 produce customized drug delivery systems. *Int J Pharm* 2017,528:268-279.
26
27
28
29
30 101. Blaesi AH, Saka N. 3D-micro-patterned fibrous dosage forms for immediate drug release.
31 *Mater Sci Eng C Mater Biol Appl* 2018,84:218-229.
32
33
34
35 102. Fuenmayor E, Forde M, Healy AV, Devine DM, Lyons JG, McConville C Major I. Comparison
36 of fused-filament fabrication to direct compression and injection molding in the manufacture
37 of oral tablets. *Int J Pharm* 2019,558:328-340.
38
39
40
41
42 103. Fuenmayor E, O'Donnell C, Gately N, Doran P, Devine DM, Lyons JG, McConville C, Major
43 I. Mass-customization of oral tablets via the combination of 3D printing and injection molding.
44 *Int J Pharm* 2019, 569:118611.
45
46
47
48 104. Trenfield SJ, Xian Tan H, Awad A, Buanz A Gaisford, S, Basit AW, Goyanes A. Track-and-
49 trace: novel anti-counterfeit measures for 3D printed personalized drug products using smart
50 material inks. *Int J Pharm* 2019,567:118443.
51
52
53
54
55 105. Dumpa NR, Bandari S, Repka MA. Novel gastroretentive floating pulsatile drug delivery
56 system produced via hot-melt extrusion and fused deposition modeling 3D printing.
57 *Pharmaceutics* 2020,12:52.
58
59
60

- 1
2
3 106. Eleftheriadis GK, Katsiotis CS, Bouropoulos N, Koutsopoulos S, Fatouros DG. FDM-printed
4 pH-responsive capsules for the oral delivery of a model macromolecular dye. *Pharm Dev*
5
6
7
8
9
10
11 107. Goyanes A, Fernández-Ferreiro A, Majeed A, Gomez-Lado N, Awad A, Luaces-Rodríguez A,
12
13
14
15
16
17 108. Krause J, Bogdahn M, Schneider F, Koziolok M, Weitschies W. Design and characterization of
18
19
20
21
22
23
24 109. Markl D, Zeitler A, Rades T, Rantanen J, Bøtker J. Toward quality assessment of 3D printed
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
110. Okwuosa TC, Soares C, Gollwitzer V, Habashy R, Timmins P, Alhnan MA. On demand manufacturing of patient-specific liquid capsules via co-ordinated 3D printing and liquid dispensing. *Eur J Pharm Sci* 2018,118:134-143.
111. Smith D, Kapoor Y, Hermans A, Nofsinger R, Kesisoglou F, Gustafson TP, Procopio A. 3D printed capsules for quantitative regional absorption studies in the GI tract. *Int J Pharm* 2018,550:418-428.
112. Smith DM, Kapoor Y, Klinzing GR, Procopio AT. Pharmaceutical 3D printing: design and qualification of a single step print and fill capsule. *Int J Pharm* 2018,544:21-30.
113. Zhao J, Xu X, Wang M, Wang L. A new model of a 3D-printed shell with convex drug release profile. *Dissolut Technol* 2018,25:24-28.
114. Charoenying T, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Akkaramongkolporn P, Opanasopit P. Fabrication of floating capsule-in- 3D-printed devices as gastro-retentive delivery systems of amoxicillin. *J Drug Deliv Sci Technol* 2020,55:101393.

- 1
2
3 115. Fu J, Yin H, Yu X, Xie C, Jiang H, Jin Y, Shen F. Combination of 3D printing technologies
4 and compressed tablets for preparation of riboflavin floating tablet-in-device (TiD) systems. Int
5 J Pharm 2018,549:370-379.
6
7
8
9
10 116. Genina N, Boetker J, Colombo S, Harmankaya N, Rantanen J, Bohr A. Anti-tuberculosis drug
11 combination for controlled oral delivery using 3D printed compartmental dosage forms: from
12 drug product design to *in vivo* testing. J Control Release 2017,268:40-48.
13
14
15
16
17 117. Huanbutta K, Sangnim T. Design and development of zero-order drug release gastroretentive
18 floating tablets fabricated by 3D printing technology. J Drug Deliv Sci Technol 2019,52:831-
19 837.
20
21
22
23
24 118. Maroni A, Melocchi A, Parietti F, Foppoli A, Zema L, Gazzaniga A. 3D printed multi-
25 compartment capsular devices for two-pulse oral drug delivery. J Control Release 2017,268:10-
26 18.
27
28
29
30
31 119. Matijašić G, Gretić M, Vinčić J, Poropat A, Cuculić L, Rahelić T. Design and 3D printing of
32 multi-compartmental PVA capsules for drug delivery. J Drug Deliv Sci Technol 2019,52:677-
33 686.
34
35
36
37
38 120. Melocchi A, Parietti F, Maccagnan S, Ortenzi MA, Antenucci S, Briatico-Vangosa F, Maroni
39 A, Gazzaniga A, Zema L. Industrial development of a 3D-printed nutraceutical delivery
40 platform in the form of a multicompartment HPC capsule. AAPS PharmSciTech 2018,19:3343-
41 3354.
42
43
44
45
46
47 121. Melocchi A, Uboldi M, Parietti F, Cerea M, Foppoli A, Palugan L, Gazzaniga A, Maroni A,
48 Zema L. Lego-inspired capsular devices for the development of personalized dietary
49 supplements: proof of concept with multimodal release of caffeine. J Pharm Sci 2020, doi:
50 10.1016/j.xphs.2020.02.013.
51
52
53
54
55
56 122. Nober C, Manini G, Carlier E, Raquez J-M, Benali S, Dubois P, Amighi K, Goole J. Feasibility
57 study into the potential use of fused-deposition modeling to manufacture 3D-printed enteric
58 capsules in compounding pharmacies. Int J Pharm 2019,569:118581.
59
60

- 1
2
3 123. Shin S, Kim TH, Jeong SW, Chung SE, Lee DY, Kim D-H, Shin B.S. Development of a
4 gastroretentive delivery system for acyclovir by 3D printing technology and its *in vivo*
5 pharmacokinetic evaluation in Beagle dogs. PLoS ONE 2019,14:e0216875.
6
7
8
9
10 124. Gioumouxouzis CI, Chatzitaki A-T, Karavasili C, Katsamenis OL, Tzetzis D, Mystiridou E,
11 Bouropoulos N, Fatouros DG. Controlled release of 5-fluorouracil from alginate beads
12 encapsulated in 3D printed pH-responsive solid dosage forms. AAPS PharmSciTech
13 2018,19:3362-3375.
14
15
16
17
18
19 125. Linares V, Casas M, Caraballo I. Printfills: 3D printed systems combining fused deposition
20 modeling and injection volume filling. Application to colon-specific drug delivery. Eur J Pharm
21 Biopharm 2019, 134:138-143.
22
23
24
25
26 126. Kim TH, Lee J-H, Ahn CB, Hong JH, Son KH, Lee JW. Development of a 3D-printed drug-
27 eluting stent for treating obstructive salivary gland disease. ACS Biomater Sci Eng
28 2019,5:3572-3581.
29
30
31
32
33 127. Misra SK, Ostadhossein F, Babu R, Kus J, Tankasala D Sutrisno A, Walsh KA, Bromfield CR,
34 Pan D. 3D-printed multidrug-eluting stent from graphene-nanoplatelet-doped biodegradable
35 polymer composite. Adv HealthcMater. 2017,6:1700008
36
37
38
39
40 128. Zhang Y, Zhao J, Yang G, Zhou Y, Gao W, Wu G, Li X, Mao C, Sheng T, Zhou M. Mechanical
41 properties and degradation of drug eluted bioresorbable vascular scaffolds prepared by three-
42 dimensional printing technology. J Biomater Sci Polym Ed 2019,30:547-560.
43
44
45
46
47 129. Benmassaoud MM, Kohama C, Kim TWB, Kadlowec JA, Foltiny B, Mercurio T, Ranganathan,
48 SI. Efficacy of eluted antibiotics through 3D printed femoral implants. Biomed Microdevices
49 2019,21:51.
50
51
52
53
54 130. Kim TWB, Lopez OJ, Sharkey JP, Marden KR, Murshed MR, Ranganathan SI. 3D printed liner
55 for treatment of periprosthetic joint infections. Med Hypotheses 2017,102:65-68.
56
57
58
59 131. Chou Y-C, Lee D, Chang T-M, Hsu Y-H, Yu Y-H, Chan E-C, Liu S-J, Combination of a
60 biodegradable three-dimensional (3D) - printed cage for mechanical support and nanofibrous

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

membranes for sustainable release of antimicrobial agents for treating the femoral metaphyseal comminuted fracture. *J Mech Behav Biomed Mater* 2017,72:209-218.

132. Zhang Z-Z, Zhang H-Z, Zhang Z-Y. 3D printed poly(ϵ -caprolactone) scaffolds function with simvastatin-loaded poly(lactic-co-glycolic acid) microspheres to repair load-bearing segmental bone defects. *Exp Ther Med* 2019, 17:79-90.
133. Chen S, Zhu L, Wen W, Lu L, Zhou C, Luo, B. Fabrication and evaluation of 3D printed poly(l-lactide) scaffold functionalized with quercetin-polydopamine for bone tissue engineering. *ACS Biomate Sci Eng* 2019,5:2506-2518.
134. Costa PF, Puga AM, Díaz-Gomez L, Concheiro A, Busch DH, Alvarez-Lorenzo C. Additive manufacturing of scaffolds with dexamethasone controlled release for enhanced bone regeneration. *Int J Pharm* 2015,496:541-550.
135. Dang HP, Shabab T, Shafiee A, Peiffer QC, Fox K, Tran N, Dargaville TR., Hutmacher DW, Tran PA. 3D printed dual macro-, **microscale** porous network as a tissue engineering scaffold with drug delivering function. *Biofabrication* 2019,11:035014.
136. Domínguez-Robles J, Mancinelli C, Mancuso E, Romero IG, Gilmore BF, Casettari L, Larrañeta E, Lamprou DA. 3D printing of drug-loaded thermoplastic polyurethane meshes: a potential material for soft tissue reinforcement in vaginal surgery. *Pharmaceutics* 2020,12:63.
137. Farto-Vaamonde X, Auriemma G, Aquino RP, Concheiro A, Alvarez-Lorenzo C. Post-manufacture loading of filaments and 3D printed PLA scaffolds with prednisolone and dexamethasone for tissue regeneration applications. *Eur J Pharm Biopharm* 2019,141:100-110.
138. Genina N, Holländer J, Jukarainen H Mäkilä, E, Salonen J, Sandler N. Ethylene vinyl acetate (EVA) as a new drug carrier for 3D printed medical drug delivery devices. *Eur J Pharm Sci* 2016,90:53-63.
139. Holländer J, Genina N, Jukarainen H, Khajeheian M, Rosling A, Mäkilä E, Sandler N. Three-dimensional printed PCL-based implantable prototypes of medical devices for controlled drug delivery. *J Pharm Sci* 2016,105:2665-2676.

- 1
2
3 140. Kempin W, Franz C, Koster L-C, Schneider F, Bogdahn M, Weitschies W, Seidlitz A.
4
5 Assessment of different polymers and drug loads for fused deposition modeling of drug loaded
6
7 implants. *Eur J Pharm Biopharm* 2017,115:84-93.
8
9
10 141. Li X, Wang Y, Wang Z, Qi Y, Li L, Zhang P, Chen X, Huang Y. Composite
11
12 PLA/PEG/nHA/dexamethasone scaffold prepared by 3D printing for bone regeneration.
13
14 *Macromol Biosci* 2018,18:1800068.
15
16
17 142. Qamar N, Abbas N, Irfan M, Hussain A, Arshad MS, Latif S, Mehmood F, Ghori MU.
18
19 Personalized 3D printed ciprofloxacin impregnated meshes for the management of hernia. *J*
20
21 *Drug Deliv Sci Technol* 201953:10116.
22
23
24 143. Visscher LE, Dang HP, Knackstedt MA, Hutmacher DW, Tran PA. 3D printed
25
26 polycaprolactone scaffolds with dual macro-microporosity for applications in local delivery of
27
28 antibiotics. *Mater Sci Eng C Mater Biol Appl* 2018,87:78-89.
29
30
31 144. Water JJ, Bohr A, Boetker J, Aho J, Sandler N, Nielsen HM, Rantanen J. Three-dimensional
32
33 printing of drug-eluting implants: Preparation of an antimicrobial polylactide feedstock
34
35 material. *J Pharm Sci* 2015,104:1099-1107.
36
37
38 145. Yi H-G, Choi Y-J, Kang KS, Hong JM, Pati RG, Park MN, Shim IK, Lee CM, Kim SC, Cho
39
40 D-W. A 3D-printed local drug delivery patch for pancreatic cancer growth suppression. *J*
41
42 *Control Release* 2016,238:231-241.
43
44
45 146. Lim SH, Chia SMY, Kang L, Yap KY-L. Three-dimensional printing of carbamazepine
46
47 sustained-release scaffold. *J Pharm Sci* 2016,105:2155-2163.
48
49
50 147. Auvinen V-V, Virtanen J, Merivaara A, Virtanen V, Laurén P, Tuukkanen S, Laaksonen T.
51
52 Modulating sustained drug release from nanocellulose hydrogel by adjusting the inner geometry
53
54 of implantable capsules. *J Drug Deliv Sci Technol* 2020,57:101625.
55
56
57 148. Stewart SA, Domínguez-Robles J, Mcllorum VJ, Mancuso E, Lamprou DA, Donnelly RF,
58
59 Larrañeta E. Development of a biodegradable subcutaneous implant for prolonged drug
60
61 delivery using 3D printing. *Pharmaceutics* 2020,12:105.

- 1
2
3 149. Yang N, Chen H, Han H, Shen Y, Gu S, He Y, Guo S. 3D printing and coating to fabricate a
4 hollow bullet-shaped implant with porous surface for controlled cytoxan release. *Int J Pharm*
5 2018,552:91-98.
6
7
8
9
10 150. Zhou Z, Yao Q, Li L, Zhang X, Wei B, Yuan L, Wang L. Antimicrobial activity of 3D-printed
11 poly(ϵ -caprolactone) (PCL) composite scaffolds presenting vancomycin-loaded polylactic
12 acid-glycolic acid (PLGA) microspheres. *Med Sci Monit* 2018,24:6934-6945.
13
14
15
16
17 151. Goyanes A, Det-Amornrat U, Wang J, Basit AW, Gaisford S. 3D scanning and 3D printing as
18 innovative technologies for fabricating personalized topical drug delivery systems. *J Control*
19 *Release* 2016,234:41-48.
20
21
22
23
24 152. Muwaffak Z, Goyanes A, Clark V, Basit AW, Hilton ST, Gaisford S. Patient-specific 3D
25 scanned and 3D printed antimicrobial polycaprolactone wound dressings. *Int J Pharm*
26 2017,527:161-170.
27
28
29
30
31 153. Luzuriaga MA, Berry DR, Reagan JC, Smaldone RA, Gassensmith JJ. Biodegradable 3D
32 printed polymer microneedles for transdermal drug delivery. *Lab Chip* 2018,18:1223-1230.
33
34
35
36 154. Fu J, Yu X, Jin Y. 3D printing of vaginal rings with personalized shapes for controlled release
37 of progesterone. *Int J Pharm* 2018,539:75-82.
38
39
40 155. Welsh NR, Malcolm RK, Devlin B, Boyd P. Dapivirine-releasing vaginal rings produced by
41 plastic freeforming additive manufacturing. *Int J Pharm* 2019,572:118725.
42
43
44
45 156. Melocchi A, Inverardi N, Uboldi M, Baldi F, Maroni A, Pandini S, Briatico-Vangosa F, Zema
46 L, Gazzaniga A. Retentive device for intravesical drug delivery based on water-induced shape
47 memory response of poly(vinyl alcohol): design concept and 4D printing feasibility. *Int J Pharm*
48 2019,559:299-311.
49
50
51
52
53
54 157. Persaud S, Eid S, Swiderski N, Serris I, Cho H. Preparations of rectal suppositories containing
55 artesunate. *Pharmaceutics* 2020,12:222.
56
57
58
59 158. Tagami T, Hayashi N, Sakai N, Ozeki T. 3D printing of unique water-soluble polymer-based
60 suppository shell for controlled drug release. *Int J Pharm* 2019,568:118494.

- 1
2
3 159. Alhijaj M, Belton P, Qi S. An investigation into the use of polymer blends to improve the
4 printability of and regulate drug release from pharmaceutical solid dispersions prepared *via*
5 fused deposition modeling (FDM) 3D printing. *Eur J Pharm Biopharm* 2016,108:111-125.
6
7
8
9
10 160. Alhijaj M, Nasereddin J, Belton P, Qi S. Impact of processing parameters on the quality of
11 pharmaceutical solid dosage forms produced by fused deposition modeling (FDM).
12 *Pharmaceutics* 2019,11:633.
13
14
15
16 161. Davies MJ, Costley E, Ren J, Gibbons P, Kondor A, Naderi M. On drug-base incompatibilities
17 during extrudate manufacture and fused deposition 3D printing. *J 3D Print Med* 2017,1:31-47.
18
19
20
21 162. Feuerbach T, Kock S, Thommes M. Characterisation of fused deposition modeling 3D printers
22 for pharmaceutical and medical applications. *Pharm Dev Technol* 2018,23:1136-1145.
23
24
25
26 163. Fuenmayor E, Forde M, Healy AV, Devine DM, Lyons JG, McConville C, Major I. Material
27 considerations for fused-filament fabrication of solid dosage forms. *Pharmaceutics* 2018,10:44.
28
29
30
31 164. Ilyés K, Kovács NK, Balogh A, Borbás E, Farkas B, Casian T, Marosi G, Tomuța I, Nagy ZK.
32 The applicability of pharmaceutical polymeric blends for the fused deposition modelling
33 (FDM) 3D technique: material considerations - printability - process modulation. with
34 consecutive effects on *in vitro* release, stability and degradation. *Eur J Pharm Sci* 2019,129:
35 110-123.
36
37
38
39
40
41
42 165. Korte C, Quodbach J. Formulation development and process analysis of drug-loaded filaments
43 manufactured *via* hot-melt extrusion for 3D-printing of medicines. *Pharm Dev Technol*
44 2018,23:1117-1127.
45
46
47
48
49 166. Melocchi A, Parietti F, Maroni A, Foppoli A, Gazzaniga A, Zema L. Hot-melt extruded
50 filaments based on pharmaceutical grade polymers for 3D printing by fused deposition
51 modeling. *Int J Pharm* 2016,509:255-263.
52
53
54
55
56 167. Petersmann S, Spoerk M, Van De Steene W, Üçal M, Wiener J, Pinter G, Arbeiter F.
57 Mechanical properties of polymeric implant materials produced by extrusion-based additive
58 manufacturing. *J Mech Behav Biomed Mater* 2020,104:103611.
59
60

- 1
2
3 168. Tagami T, Fukushige K, Ogawa E, Hayashi N, Ozeki T. 3D printing factors important for the
4 fabrication of polyvinyl alcohol filament-based tablets. *Biol Pharm Bull* 2017,40:357-364.
5
6
7 169. Zhang J, Xu P, Vo AQ, Bandari S, Yang F, Durig T, Repka MA. Development and evaluation
8 of pharmaceutical 3D printability for hot melt extruded cellulose-based filaments. *J Drug Deliv*
9 *Sci Technol* 2019,52:292-302.
10
11
12
13
14 170. Jiang H, Fu J, Li M, Wang S, Zhuang B, Sun H, Ge C, Feng B, Jin Y. 3D-printed wearable
15 personalized orthodontic retainers for sustained release of clonidine hydrochloride. *AAPS*
16 *PharmSciTech* 2019,20: 260.
17
18
19
20
21 171. Liang K, Carmone S, Brambilla D, Leroux J-C. 3D printing of a wearable personalized oral
22 delivery device: a first-in-human study. *Sci Adv* 2018,4:eaat2544.
23
24
25
26 172. Long J, Nand AV, Ray S, Mayhew S, White D, Bunt CR, Seyfoddin A. Development of
27 customised 3D printed biodegradable projectile for administrating extended-release
28 contraceptive to wildlife. *Int J Pharm* 2018,548:349-356.
29
30
31
32
33 173. Mathew E, Domínguez-Robles J, Stewart SA, Mancuso E, O'Donnell K, Larrañeta E, Lamprou
34 DA. Fused deposition modeling as an effective tool for anti-infective dialysis catheter
35 fabrication. *ACS Biomater Sci Eng* 2019,5:6300-6310.
36
37
38
39
40 174. Weisman JA, Jammalamadaka U, Tappa K, Nicholson JC, Ballard DH, Wilson C.G,
41 D'Agostino H, Mills DK. 3D printing antibiotic and chemotherapeutic eluting catheters and
42 constructs. *J Vasc Interv Radiol* 2015,26:S12.
43
44
45
46
47 175. Weisman JA, Ballard DH, Jammalamadaka U, Tappa K, Sumerel J, D'Agostino HB, Mills DK,
48 Woodard PK. 3D printed antibiotic and chemotherapeutic eluting catheters for potential use in
49 interventional radiology: *in vitro* proof of concept study. *Acad Radiol* 2019,26:270-274.
50
51
52
53
54 176. Aho J, Bøtker JP, Genina N, Edinger M, Arnfast L, Rantanen J. Roadmap to 3D-printed oral
55 pharmaceutical dosage forms: feedstock filament properties and characterization for fused
56 deposition modeling. *J Pharm Sci* 2019,108:26-35.
57
58
59
60

- 1
2
3 177. Araújo MRP, Sa-Barreto LL, Gratieri T, Gelfuso GM, Cunha-Filho M. The digital pharmacies
4 era: how 3D printing technology using fused deposition modeling can become a reality.
5
6
7
8
9
10
11 178. Azad MA, Olawuni D, Kimbell G, Badruddoza AZM, Hossain MS, Sultana T. Polymers for
12 extrusion-based 3D printing of pharmaceuticals: a holistic materials-process perspective.
13
14
15
16
17 179. Cunha-Filho M, Araújo MRP, Gelfuso GM, Gratieri T. FDM 3D printing of modified drug-
18 delivery systems using hot melt extrusion: a new approach for individualized therapy. *Ther*
19
20
21
22
23
24 180. Joo Y, Shin I, Ham G, Abuzar S, Hyun S-M, Hwang S-J. The advent of a novel manufacturing
25 technology in pharmaceuticals: superiority of fused deposition modeling 3D printer. *J Pharm*
26
27
28
29
30
31 181. Long J, Gholizadeh H, Lu J, Bunt C, Seyfoddin A. Application of fused deposition modelling
32 (FDM) method of 3D printing in drug delivery. *Curr Pharm Des* 2017,23:433-439.
33
34
35
36 182. Melocchi A, Uboldi M, Maroni A, Foppoli A, Palugan L, Zema L, Gazzaniga A. 3D printing
37 by fused deposition modeling of single- and multi-compartment hollow systems for oral
38 delivery - A review. *Int J Pharm* 2020,579:119155.
39
40
41
42 183. Tan DK, Maniruzzaman M, Nokhodchi A. Advanced pharmaceutical applications of hot-melt
43 extrusion coupled with fused deposition modelling (FDM) 3D printing for personalised drug
44 delivery. *Pharmaceutics* 2018,10:203.
45
46
47
48
49 184. Rycerz K, Stepień KA, Czapiewska M, Arafat BT, Habashy R, Isreb A, Peak M, Alhnan MA.
50 Embedded 3D printing of novel bespoke soft dosage form concept for pediatrics. *Pharmaceutics*
51
52
53
54 2019,11:630.
55
56 185. Tan YJN, Yong WP, Kochhar JS, Khanolkar J, Yao X, Sun Y, Ao CK, Soh S. On-demand fully
57 customizable drug tablets via 3D printing technology for personalized medicine. *J Control*
58
59
60
60 Release 2020,332:42-52.